{"pageContent": "Background: The optimal hormone treatment strategy in prostate cancer is uncertain, particularly in patients with metastatic disease. We aimed to compare the relative benefits and harms of intermittent androgen deprivation (IAD) to continuous androgen deprivation (CAD) in all stages of prostate cancer.", "metaData": {"source": "Preface: Novel Therapeutic Targets and Biomarkers in Prostate Cancer\nhttps://pubmed.ncbi.nlm.nih.gov/35993975/"}}